KEAP1 and non-small cell lung carcinoma: To target LKB1-KEAP1 co-mutant NSCLC, we utilized Canagliflozin, an FDA-approved sodium-glucose co-transporter 2 (SGLT2) inhibitor that mimics glucose starvation via inhibiting glucose uptake, in combination with Brusatol, an inhibitor of NRF2 signalling.